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In this editorial, the issues related to the hyperbaric oxygen therapy and its utility in managing cerebral vasospasm
in patients with subarachnoid hemorrhage is discussed.
Keywords: Oxygen, Cerebral vasospasm, Subarachnoid hemorrhageCerebral vasospasm, defined as stenosis of intracranial
arteries, is one of the main causes of morbidity and mor-
tality in patients with subarachnoid hemorrhage (SAH).
The incidence peaks around the seventh day after SAH
and at that time some degree of vasospasm is evident on
up to 70% of cerebral angiograms [1]. Symptoms related
to vasospasm appear with at least a 50% reduction in ar-
terial caliber [2] and occurs in about a quarter of
patients with SAH [3]. It is an important cause of cere-
bral ischemia and leading, though potentially treatable,
cause of morbidity and mortality after SAH [1]. Develop-
ment of vasospasm is best predicted by the amount of
subarachnoid blood early after SAH (the amount of
bleeding is assessed by computed tomography (CT)
scanning and is graded according to the Fisher CT
grade) [4]. Gold standard for diagnosis is cerebral angi-
ography [5]. Noninvasive imaging techniques including
CT angiography, CT perfusion, or transcranial Doppler
ultrasound (TCD) are frequently obtained, but generally
less accurate. Currently, the mainstay of prevention and
treatment includes optimization of cerebral blood flow
through systemic administration of nimodipine, hyperdy-
namic therapy, and pharmacologic of mechanical angio-
plasty [2]. Notably, hyperbaric oxygen therapy stands as a
potentially new, cost-effective and safe method for man-
aging cerebral vasospasm [6,7]. Hyperbaric oxygen therapy
not only protects the hypoperfused brain tissue from
ischemia but also improves cerebral perfusion by reducing
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distribution, and reproduction in any mediumVasospasm creates a state of focal ischemia in the area
irrigated by the stenotic vessel. Numerous studies have
demonstrated a neuroprotective effect of hyperbaric oxy-
gen in experimental animal models of focal ischemic
brain injury and SAH [8]. Clinical trials of hyperbaric
oxygen as a treatment for patients with symptomatic
cerebrovascular disease and lacunar infarctions [9] and
in prevention of neuropsychometric dysfunction after
coronary bypass grafting [10] have shown promising
results. Hyperbaric oxygen therapy is defined as a fraction
of inspired oxygen administered at supra-atmospheric
pressure in a hyperbaric oxygen chamber. Hyperbaric
oxygen increases oxygen tension in the brain to levels
where normal neuronal metabolism is maintained even in
absence of hemoglobin delivered oxygen. Hyperbaric oxy-
gen has variable effect on the cerebral blood flow and
appears to reduce intracranial pressure [8]. Decreased
brain infarction and improved neurobehavioral perform-
ance with hyperbaric oxygen therapy have been attributed
to reduced blood–brain barrier breakdown, a decrease in
inflammatory response, reduced oxidative and excitotoxic
stress, decreased apoptosis and improved neural regene-
ration [1].
Transient exposure to hyperbaric oxygen appears to be
benign in healthy human subjects even though extreme
hyperbaric conditions above 4 to 5 atmosphere absolute
(ATA) may result in brain oxygen toxicity and suscepti-
bility to seizures [11]. Limitations of the hyperbaric oxy-
gen therapy include its practicality and applicability in
clinical practice given the necessity to have a hyperbaric
oxygen chamber. Initiation of hyperbaric therapy in
close temporal relationship to the onset of ischemia cre-
ates another challenge as delayed administration mightentral Ltd. This is an Open Access article distributed under the terms of the
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sient brain ischemia, a delayed hyperbaric therapy aggra-
vated the ischemic brain injury both histologically and
clinically [12,13].
In a study [14], patients with aneurysmal SAH from an
anterior circulation aneurysm were randomly assigned
to receive at least 20 daily hyperbaric therapy (2 ATA)
sessions lasting 60 minutes including pressurization and
depressurization starting within one to three days from
their aneurysm surgery. A total of 120 patients were
included and randomized in equal proportions to hyper-
baric therapy or control group. Primary endpoint was
Glasgow Outcome Score at 6 months, and secondary
endpoints included middle cerebral artery flow velocities
measured by TCD, abnormal density in the operative
region as a surrogate for cerebral infarction or edema,
cases of symptomatic vasospasm, and Karnofsky Perform-
ance Scale (KPS). Symptomatic vasospasm was defined as
development of a focal neurological deficit or deterior-
ation in level of consciousness between the 3rd and 14th
day after surgery associated with an increase in mean
TCD velocity of 120 cm/sec in the investigated territory.
The hyperbaric oxygen group performed favorably in
terms of mean TCD velocities at days 7 and 14, smaller
abnormal density volumes at days 7, 14, and 21, a smaller
number of symptomatic vasospasm patients on days 7
and 14, higher KPS scores on day 21, and more patients
with GOS 4 and 5 at 6 months. All these findings were
statistically significant.
The utility of hyperbaric oxygen therapy in treatment
of cerebral vasospasm sounds quite interesting and sig-
nals a new line of related studies to further underpin its
advantages and disadvantages over current therapies.
Current evidence of hyperbaric oxygen as a treatment of
cerebral vasospasm is interesting. Ceverbral vasospasm
is a potentially devastating complication of SAH and is
urgently in need of a definitive treatment. Therefore, fu-
ture randomized clinical trials are desired to investigate
the utility of hyperbaric oxygen therapy in managing this
condition.
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